Ilana S. Rosman

Ilana S. Rosman

Auto-generated profile, based on publicly available information

Ilana S. Rosman

Department of Dermatology, Washington University School of Medicine, St Louis, MO, United States

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2006 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JKJian Kong
Jian Kong
RGRandy L. Gollub
Randy L. Gollub
IRIlana S. Rosman
Ilana S. Rosman
JWJ. Megan Webb
J. Megan Webb
MVMark G. Vangel
Mark G. Vangel
TKTed J. Kaptchuk
Ted J. Kaptchuk
In this study, a well established expectancy manipulation model was combined with a novel placebo intervention, a validated sham acupuncture needle, to investigate the brain network involved in placebo analgesia. Sixteen subjects completed the experiment. We found that after placebo acupuncture treatment, subjective pain rating reduction (pre minus post) on the placebo-treated side was significantly greater than on the control side. When we calculated the contrast that subtracts the functional magnetic resonance imaging (fMRI) signal difference between post-treatment and pretreatment during pain application on placebo side from the same difference on control side [e.g., placebo (post – pre) – control (post – pre)], significant differences were observed in the bilateral rostral anterior cingulate cortex (rACC), lateral prefrontal cortex, right anterior insula, supramarginal gyrus, and left inferior parietal lobule. The simple regression (correlation) analysis between each subject's fMRI signal difference of post-treatment and pretreatment difference on placebo and control side and the corresponding subjective pain rating difference showed that significant negative correlation was observed in the bilateral lateral/orbital prefrontal cortex, rACC, cerebellum, right fusiform, parahippocampus, and pons. These results are different from a previous study that found decreased activity in pain-sensitive regions such as the thalamus, insula, and ACC when comparing the response to noxious stimuli applied to control and placebo cream-treated areas of the skin. Our results suggest that placebo analgesia may be configured through multiple brain pathways and mechanisms.

9 December 2005 in Human Brain Mapping
Verified
Journal Article
Closed access
JKJian Kong
Jian Kong
NWNathan S. White
Nathan S. White
KKKenneth K. Kwong
Kenneth K. Kwong
MVMark G. Vangel
Mark G. Vangel
IRIlana S. Rosman
Ilana S. Rosman
RGRandy L. Gollub
Randy L. Gollub

1 January 2005 in The Journal of Pain
Verified
Journal Article
Closed access
JKJian Kong
Jian Kong
DFDuretti T. Fufa
Duretti T. Fufa
AGAndrew J. Gerber
Andrew J. Gerber
IRIlana S. Rosman
Ilana S. Rosman
MVMark G. Vangel
Mark G. Vangel
RGRandy L. Gollub
Randy L. Gollub

21 March 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
ARAbby R. Rosenberg
Abby R. Rosenberg
MTMary Tabacchi
Mary Tabacchi
KNKenneth H. Ngo
Kenneth H. Ngo
MWMichael Wallendorf
Michael Wallendorf
IRIlana S. Rosman
Ilana S. Rosman
SDShadmehr Demehri
Shadmehr Demehri
BACKGROUND. Topical calcipotriol plus 5-fluorouracil (5-FU) combination is an effective immunotherapy against actinic keratosis (AK), which is a precursor to squamous cell carcinoma (SCC). However, the long-term effectiveness of calcipotriol plus 5-FU treatment for SCC prevention is unknown. METHODS. We performed a blinded prospective cohort study on participants of a randomized double-blind clinical trial in which a 4-day course of topical calcipotriol plus 5-FU combination was compared to Vaseline plus 5-FU (control) for AK treatment. SCC and basal cell carcinoma (BCC) incidences were assessed at 1, 2, and 3 years after trial. Tissues were analyzed for calcipotriol plus 5-FU–induced T cell immunity in the skin. RESULTS. Calcipotriol plus 5-FU–induced tissue-resident memory T (Trm) cell formation in face and scalp skin associated with significantly higher erythema scores compared with control ( P < 0.01). Importantly, more participants in the test cohort remained SCC-free over the more than 1,500-day follow-up period ( P = 0.0765), and significantly fewer developed SCC on the treated face and scalp within 3 years (2 of 30 [7%] versus 11 of 40 [28%] in control group, hazard ratio 0.215 [95% CI: 0.048–0.972], P = 0.032). Accordingly, significantly more epidermal Trm cells persisted in the calcipotriol plus 5-FU–treated face and scalp skin compared with control ( P = 0.0028). There was no significant difference in BCC incidence between the treatment groups. CONCLUSION. A short course of calcipotriol plus 5-FU treatment on the face and scalp is associated with induction of robust T cell immunity and Trm formation against AKs and significantly lowers the risk of SCC development within 3 years of treatment. FUNDING. This research was supported by internal academic funds and by grants from the Burroughs Wellcome Fund, Sidney Kimmel Foundation, Cancer Research Institute, and NIH.

1 June 2017 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LBLynn M Boyden
Lynn M Boyden
NVNicholas G Vincent
Nicholas G Vincent
JZJing Zhou
Jing Zhou
RHRonghua Hu
Ronghua Hu
BCBrittany G Craiglow
Brittany G Craiglow
KCKeith A Choate
Keith A Choate

1 June 2017 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YZYong Zhou
Yong Zhou
STShivani V. Tripathi
Shivani V. Tripathi
IRIlana Rosman
Ilana Rosman
JMJun Ma
Jun Ma
PHPengfei Hai
Pengfei Hai
LCLynn A. Cornelius
Lynn A. Cornelius